• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

FDA panel supports premarket approval of stent

Article

The FDA ophthalmic devices panel supports the premarket approval of an implant (iStent Trabecular Micro-Bypass Stent Model GTS-100 L/R, Glaukos) for use in conjunction with cataract surgery to reduce IOP in patients with mild-to-moderate, open-angle glaucoma treated with ocular hypotensive medication.

Laguna Hills, CA-The FDA ophthalmic devices panel supports the premarket approval of an implant (iStent Trabecular Micro-Bypass Stent Model GTS-100 L/R, Glaukos) for use in conjunction with cataract surgery to reduce IOP in patients with mild-to-moderate, open-angle glaucoma treated with ocular hypotensive medication.

The panel reviewed data from a 12-month, prospective, randomized, open-label, multicenter, controlled clinical trial conducted at 27 sites in the United States. Members voted 7-1-0 that there is a reasonable assurance that the implant is safe for the indication, voted 6-2-0 that there is a reasonable assurance that the implant is effective for the indication, and voted 7-1-0 that the benefits outweigh the risks of the implant for the indication.

Panel members did express concerns with the overall effectiveness of the implant, noted a lack of effectiveness at 24 months, and recommended that the indication for use reflect the temporary nature of the device’s effectiveness.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.